Modality
siRNA
MOA
BCL-2i
Target
TROP-2
Pathway
Sphingolipid
Pancreatic CaThymoma
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
Mar 2017
→ May 2028
Phase 1Current
NCT04081919
51 pts·Thymoma
2017-05→2028-03·Completed
NCT03028959
2,085 pts·Pancreatic Ca
2017-03→2028-05·Completed
2,136 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-12-138mo awayOrphan Drug· Thymoma
2028-03-252.0y awayPh2 Data· Thymoma
2028-05-242.1y awayPh2 Data· Pancreatic Ca
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1/2
Complet…
P1/2
Complet…
Catalysts
Orphan Drug
2026-12-13 · 8mo away
Thymoma
Ph2 Data
2028-03-25 · 2.0y away
Thymoma
Ph2 Data
2028-05-24 · 2.1y away
Pancreatic Ca
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04081919 | Phase 1/2 | Thymoma | Completed | 51 | SeizFreq |
| NCT03028959 | Phase 1/2 | Pancreatic Ca | Completed | 2085 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D |